Clinical Trial Update: Identification of Potential Biomarkers of Response to Peptide Immunotherapy for Ragweed Allergy [Phase 2]

View source ↗

Summary

Phase 2 trial update identifying potential biomarkers of response to peptide immunotherapy for ragweed allergy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ragweed Allergy

Drugs mentioned

• Pollinex Quattro Ragweed (peptide immunotherapy)

Snippet

Sponsor: Circassia Limited | Conditions: Ragweed Allergy | Phase 2 | Status: COMPLETED